Beschrijving
This week, three developments highlight the rapidly changing rare disease treatment landscape: a Phase 3 setback in Angelman syndrome, continued competition in hereditary angioedema, and an FDA decision expanding access to a targeted lung cancer therapy.
Angelman Syndrome: Phase 3 Trial Misses Its Marks
Ultragenyx announced results from its Phase 3 Aspire study of apazunersen in Angelman syndrome. The trial did not meet its primary or key secondary endpoints.
Angelman syndrome is a rare neurodevelopmental disorder caused by the loss of a working copy of the UBE3A gene. Patients generally…
Website: spreaker.com

